Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer’s Disease

The most common cause of dementia, especially in elderly people, is Alzheimer’s disease (AD), with aging as its main risk factor. AD is a multifactorial neurodegenerative disease. There are several factors increasing the risk of AD development. One of the main features of Alzheimer’s disease is impa...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-08, Vol.22 (15), p.8142
Main Author: Szablewski, Leszek
Format: Article
Language:English
Subjects:
Aging
Alzheimer's disease
Antidiabetics
Axonal transport
Brain
Dementia
Dementia disorders
Diabetes mellitus
Energy
Geriatrics
Glucose
Glucose transport
glucose transporters
Hypometabolism
Hypothalamus
Insulin
Lipids
Membranes
Metabolism
Neuronal-glial interactions
Neurons
Older people
Pathogenesis
Peptides
Physiology
Plasma
Proteins
Review
Risk analysis
Risk factors
siRNA
therapy of Alzheimer’s disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The most common cause of dementia, especially in elderly people, is Alzheimer’s disease (AD), with aging as its main risk factor. AD is a multifactorial neurodegenerative disease. There are several factors increasing the risk of AD development. One of the main features of Alzheimer’s disease is impairment of brain energy. Hypometabolism caused by decreased glucose uptake is observed in specific areas of the AD-affected brain. Therefore, glucose hypometabolism and energy deficit are hallmarks of AD. There are several hypotheses that explain the role of glucose hypometabolism in AD, but data available on this subject are poor. Reduced transport of glucose into neurons may be related to decreased expression of glucose transporters in neurons and glia. On the other hand, glucose transporters may play a role as potential targets for the treatment of AD. Compounds such as antidiabetic drugs, agonists of SGLT1, insulin, siRNA and liposomes are suggested as therapeutics. Nevertheless, the suggested targets of therapy need further investigations.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22158142